Brivanib for Hepatocellular Carcinoma Trials: Selection Bias From Barcelona Clinic Liver Cancer Stage?

Nowadays, the position of sorafenib in thetreatmentofadvancedhepatocellularcarcinoma(HCC)isfrequentlychallengedbyothermoleculartargetedagents.However,regardlessofwhether they are considered as first-line or second-line treatmentoptions,allcompletedphaseIIIrandomizedcontrolledtrials(RCTs)reportnegativeresults.Similarly,twophaseIIIRCTs(ComparisonofBrivanibandBestSupportiveCaretoPlacebo BestSupportiveCarein Subjects With Advanced Hepatocellular Cancer Who Have Failedor Are Intolerant to Sorafenib Treatment [BRISK-PS] and A Ran-domized, Double-Blind, Multi-Center Phase III Study of BrivanibVersusSorafenibAsFirst-LineTreatmentinPatientsWithAdvancedHepatocellularCarcinoma[BRISK-FL])thatwererecentlypublishedin